上海医药
(601607)
| 流通市值：500.10亿 | | | 总市值：664.91亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 215,072,230,363.46 | 141,592,782,502.79 | 70,762,515,910.94 | 275,250,934,889.66 |
| 营业收入 | 215,072,230,363.46 | 141,592,782,502.79 | 70,762,515,910.94 | 275,250,934,889.66 |
| 二、营业总成本 | 209,405,979,454.06 | 137,611,880,810.19 | 68,666,635,360.52 | 267,676,306,689.98 |
| 营业成本 | 192,652,536,770.53 | 126,660,060,598.69 | 63,506,163,809.96 | 244,619,261,051.98 |
| 税金及附加 | 635,973,141.24 | 415,653,784.26 | 203,040,337.53 | 777,882,162.93 |
| 销售费用 | 9,318,311,278.74 | 6,164,987,968.04 | 2,761,184,548.83 | 12,713,976,431.27 |
| 管理费用 | 4,168,813,594.9 | 2,662,454,335.7 | 1,324,505,376.52 | 5,689,841,057.16 |
| 研发费用 | 1,515,479,406.31 | 958,949,406.87 | 497,023,575.09 | 2,394,433,810.21 |
| 财务费用 | 1,114,865,262.34 | 749,774,716.63 | 374,717,712.59 | 1,480,912,176.43 |
| 其中:利息费用 | 1,280,705,456.13 | 887,687,766.56 | 444,079,216.64 | 1,856,737,428.35 |
| 其中:利息收入 | 270,229,488.53 | -176,380,262.05 | 83,493,464.18 | -522,385,724.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 113,140,103.93 | 75,751,833.73 | 37,803,333.92 | 203,853,796.87 |
| 加:投资收益 | 3,370,051,879.37 | 3,257,333,100.37 | 171,737,957.97 | 380,426,728.73 |
| 资产处置收益 | 160,093,351.68 | 39,986,393.32 | -903,048.37 | 187,967,998.85 |
| 资产减值损失(新) | -789,412,133.56 | -410,078,463.89 | 33,522,644.21 | -614,373,564.47 |
| 信用减值损失(新) | -624,800,914.09 | -423,970,881.72 | -255,373,359.39 | -226,162,119.97 |
| 其他收益 | 441,446,271.52 | 313,695,950.14 | 63,722,035.39 | 634,371,906.48 |
| 四、营业利润 | 8,336,769,468.25 | 6,833,619,624.55 | 2,146,390,114.15 | 8,140,712,946.17 |
| 加:营业外收入 | 73,319,426.76 | 21,837,269.63 | 18,741,253.82 | 156,399,886.6 |
| 减:营业外支出 | 111,991,782.02 | 34,636,191.45 | 12,414,360.44 | 277,106,289.03 |
| 五、利润总额 | 8,298,097,112.99 | 6,820,820,702.73 | 2,152,717,007.53 | 8,020,006,543.74 |
| 减:所得税费用 | 2,311,947,675.2 | 1,826,036,672.44 | 512,523,535.93 | 2,149,995,228.86 |
| 六、净利润 | 5,986,149,437.79 | 4,994,784,030.29 | 1,640,193,471.6 | 5,870,011,314.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 5,986,149,437.79 | 4,994,784,030.29 | 1,640,193,471.6 | 5,870,011,314.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 5,147,064,933.11 | 4,458,864,876.61 | 1,333,070,453.48 | 4,552,528,438.69 |
| 少数股东损益 | 839,084,504.68 | 535,919,153.68 | 307,123,018.12 | 1,317,482,876.19 |
| 扣除非经常损益后的净利润 | 2,698,865,006.88 | 2,099,764,932.53 | 1,263,241,608.22 | 4,065,066,358.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.39 | 1.2 | 0.36 | 1.23 |
| (二)稀释每股收益 | 1.39 | 1.2 | 0.36 | 1.23 |
| 八、其他综合收益 | 14,170,692.53 | 19,680,758.31 | -3,441,851.94 | -62,617,948.59 |
| 归属于母公司股东的其他综合收益 | -3,033,432.4 | 4,161,971.75 | -6,179,668.62 | -38,190,495.76 |
| 九、综合收益总额 | 6,000,320,130.32 | 5,014,464,788.6 | 1,636,751,619.66 | 5,807,393,366.29 |
| 归属于母公司股东的综合收益总额 | 5,144,031,500.71 | 4,463,026,848.36 | 1,326,890,784.86 | 4,514,337,942.93 |
| 归属于少数股东的综合收益总额 | 856,288,629.61 | 551,437,940.24 | 309,860,834.8 | 1,293,055,423.36 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-29 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |